m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02086)
Name
RESCOVITINE
Synonyms
Rescovitine; CHEMBL1087791
    Click to Show/Hide
Status
Investigative
Structure
Formula
C19H28N6O
InChI
1S/C19H28N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,13,15,21,26H,4,10-12H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1
InChIKey
RMSINZVFNDWCCK-OAHLLOKOSA-N
PubChem CID
46881287
TTD Drug ID
D07AEC
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cyclin A2 (CCNA2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin A2 (CCNA2) is a therapeutic target for RESCOVITINE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of RESCOVITINE through regulating the expression of Cyclin A2 (CCNA2). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin A2 (CCNA2) is a therapeutic target for RESCOVITINE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RESCOVITINE through regulating the expression of Cyclin A2 (CCNA2). [1], [2]
Cyclin-dependent kinase 2 (CDK2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for RESCOVITINE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of RESCOVITINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [3]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for RESCOVITINE. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RESCOVITINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [3], [4]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for RESCOVITINE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RESCOVITINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [3]
References
Ref 1 FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1323-1330. doi: 10.1016/j.bbalip.2018.08.008. Epub 2018 Aug 13.
Ref 2 Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
Ref 3 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. doi: 10.1021/jm100080z.
Ref 4 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.